Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation

Sofia Palacio; Terri Pollack; Rachel Silva-Smith; Daniel A Sussman; Peter J Hosein

doi:10.21037/jgo.2018.03.11

Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation

J Gastrointest Oncol. 2018 Aug;9(4):E19-E22. doi: 10.21037/jgo.2018.03.11.

Authors

Sofia Palacio¹, Terri Pollack¹, Rachel Silva-Smith¹, Daniel A Sussman¹, Peter J Hosein¹

Affiliation

¹ Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA.

Abstract

Pancreatic cancer is projected to become the second leading cause of cancer death in the United States by 2030. Deleterious germline mutations can contribute to pancreatic cancer susceptibility. Herein we report a case of a patient with metastatic pancreatic adenocarcinoma to the lung and liver who was found to have a deleterious germline mutation in RAD51C who had a remarkable response to chemotherapy with FOLFIRINOX, a platinum-containing regimen.

Keywords: Pancreatic adenocarcinoma; RAD51C; oxaliplatin.

Publication types

Case Reports